Sanofi's €10bn Dupixent Plan: 'We're Going To Put The JAKs Properly In Their Place'

 
• By Jessica Merrill

Sanofi's new CEO has ambitious forecasts for Dupixent in atopic dermatitis, asthma and other indications. The French pharma outlined how it plans to reach that goal despite new competition vying to get in.

Pop art comic book style super heroine punching with female superhero costume poster design wall decoration illustration
Sanofi is ready to take on oral JAKs • Source: Shutterstock

More from Immunological

More from Therapy Areas